Zenith Epigenetics is a clinical-stage biotechnology company developing best-in-class bromodomain and extra-terminal inhibitors (BETi) for the treatment of multiple cancers and other disorders with significant unmet medical need. Our goal is to be a leading oncology company in the field of epigenetics, translating bromodomain biology into impactful, targeted therapeutics for the benefit of patients.